159 related articles for article (PubMed ID: 36035942)
41. Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors.
Parlati L; Sakka M; Retbi A; Bouam S; Hassani L; Meritet JF; Rufat P; Bonnefont-Rousselot D; Batista R; Terris B; Bellanger A; Thabut D; Vozy A; Spano JP; Coriat R; Goldwasser F; Aractingi S; Sogni P; Pol S; Mallet V; ;
JHEP Rep; 2023 Dec; 5(12):100880. PubMed ID: 38074948
[TBL] [Abstract][Full Text] [Related]
42. Immunotherapy beyond progression in patients with advanced non-small cell lung cancer.
Ge X; Zhang Z; Zhang S; Yuan F; Zhang F; Yan X; Han X; Ma J; Wang L; Tao H; Li X; Zhi X; Huang Z; Hofman P; Prelaj A; Banna GL; Mutti L; Hu Y; Wang J
Transl Lung Cancer Res; 2020 Dec; 9(6):2391-2400. PubMed ID: 33489801
[TBL] [Abstract][Full Text] [Related]
43. Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors.
Formica V; Morelli C; Patrikidou A; Murias C; Butt S; Nardecchia A; Lucchetti J; Renzi N; Shiu KK; Roselli M; Arkenau HT
Target Oncol; 2020 Jun; 15(3):327-336. PubMed ID: 32449030
[TBL] [Abstract][Full Text] [Related]
44. Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors.
Qin Z; Liu K; Xu X; Li T; Ge Y; Wu B; Xing C; Mao H
Future Oncol; 2022 May; 18(16):1951-1962. PubMed ID: 35232231
[TBL] [Abstract][Full Text] [Related]
45. Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer.
Chao Y; Zhou J; Hsu S; Ding N; Li J; Zhang Y; Xu X; Tang X; Wei T; Zhu Z; Chu Q; Neal JW; Wu JT; Song Y; Hu J
Transl Lung Cancer Res; 2022 Feb; 11(2):295-306. PubMed ID: 35280322
[TBL] [Abstract][Full Text] [Related]
46. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
[TBL] [Abstract][Full Text] [Related]
47. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
[TBL] [Abstract][Full Text] [Related]
48. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
Mountzios G; Samantas E; Senghas K; Zervas E; Krisam J; Samitas K; Bozorgmehr F; Kuon J; Agelaki S; Baka S; Athanasiadis I; Gaissmaier L; Elshiaty M; Daniello L; Christopoulou A; Pentheroudakis G; Lianos E; Linardou H; Kriegsmann K; Kosmidis P; El Shafie R; Kriegsmann M; Psyrri A; Andreadis C; Fountzilas E; Heussel CP; Herth FJ; Winter H; Emmanouilides C; Oikonomopoulos G; Meister M; Muley T; Bischoff H; Saridaki Z; Razis E; Perdikouri EI; Stenzinger A; Boukovinas I; Reck M; Syrigos K; Thomas M; Christopoulos P
ESMO Open; 2021 Oct; 6(5):100254. PubMed ID: 34481329
[TBL] [Abstract][Full Text] [Related]
49. Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis.
Zhang T; Wang Y; Shi C; Liu X; Lv S; Wang X; Li W
Front Pharmacol; 2022; 13():955701. PubMed ID: 36133806
[No Abstract] [Full Text] [Related]
50. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
Zhang S; Li S; Cheng Y
Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
[TBL] [Abstract][Full Text] [Related]
51. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Barroso-Sousa R; Barry WT; Garrido-Castro AC; Hodi FS; Min L; Krop IE; Tolaney SM
JAMA Oncol; 2018 Feb; 4(2):173-182. PubMed ID: 28973656
[TBL] [Abstract][Full Text] [Related]
52. Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis.
Chen X; Jiang A; Zhang R; Fu X; Liu N; Shi C; Wang J; Zheng X; Tian T; Liang X; Ruan Z; Yao Y
Front Cardiovasc Med; 2022; 9():882167. PubMed ID: 35669482
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Wagner G; Stollenwerk HK; Klerings I; Pecherstorfer M; Gartlehner G; Singer J
Oncoimmunology; 2020 Jun; 9(1):1774314. PubMed ID: 32923134
[TBL] [Abstract][Full Text] [Related]
54. Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System.
Lu D; Yao J; Yuan G; Gao Y; Zhang J; Guo X
Oncologist; 2022 Mar; 27(2):e126-e132. PubMed ID: 35641200
[TBL] [Abstract][Full Text] [Related]
55. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
56. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment.
Abu-Sbeih H; Tran CN; Ge PS; Bhutani MS; Alasadi M; Naing A; Jazaeri AA; Wang Y
J Immunother Cancer; 2019 May; 7(1):118. PubMed ID: 31053161
[TBL] [Abstract][Full Text] [Related]
57. Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After Immunotherapy.
Lee C; Drobni ZD; Zafar A; Gongora CA; Zlotoff DA; Alvi RM; Taron J; Rambarat PK; Schoenfeld S; Mosarla RC; Raghu VK; Hartmann SE; Gilman HK; Murphy SP; Sullivan RJ; Faje A; Hoffmann U; Zhang L; Mayrhofer T; Reynolds KL; Neilan TG
JACC CardioOncol; 2022 Dec; 4(5):660-669. PubMed ID: 36636443
[TBL] [Abstract][Full Text] [Related]
58. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Zhang N; Jiang J; Tang S; Sun G
Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
[TBL] [Abstract][Full Text] [Related]
59. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.
Chennamadhavuni A; Abushahin L; Jin N; Presley CJ; Manne A
Front Immunol; 2022; 13():779691. PubMed ID: 35558065
[TBL] [Abstract][Full Text] [Related]
60. Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults.
Schonfeld SJ; Tucker MA; Engels EA; Dores GM; Sampson JN; Shiels MS; Chanock SJ; Morton LM
JAMA Netw Open; 2022 Mar; 5(3):e223461. PubMed ID: 35315916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
